Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expert Insights on Key Data From ASH 2020 on Acute and Chronic Leukemias

December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Experts discuss results and implications from 3 of the key studies in acute myeloid leukemia and chronic myeloid leukemia from the virtual Hematology 2020 meeting, including magrolimab in AML, the STAMP inhibitor asciminib in CML (the ASCEMBL trial), and optimal dosing for ponatinib in CML (the OPTIC trial).
Jorge Cortes, MD
Eunice S. Wang, MD
Released: February 26, 2021

In this episode, Jorge Cortes, MD, and Eunice S. Wang, MD, discuss the clinical implications of 3 key studies in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) presented at the virtual ASH 2020 annual conference. Topics include:  

  • The macrophage immune checkpoint inhibitor magrolimab in AML
  • The STAMP inhibitor asciminib in CML (the ASCEMBL trial)
  • Optimal dosing for the TKI ponatinib in CML

Presenters:

Jorge Cortes, MD
Director, Georgia Cancer Center
Eminent Scholar, Georgia Research Academy
Augusta, Georgia

Eunice S. Wang, MD
Professor, Oncology
Chief, Leukemia Service
Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Related Content

Commentary from Dr. John Leonard on factors he uses to select mantle cell lymphoma therapy, from Clinical Care Options (CCO)

John P. Leonard, MD Released: July 29, 2021

Clinical commentary featuring expert insights on key CLL studies with BTK inhibitors from ASCO and EHA 2021 from Clinical Care Options (CCO)

Anthony Mato, MD, MSCE William G. Wierda, MD, PhD Released: July 28, 2021

Clinical commentary from European hematology experts on key clinical trials presented at the virtual EHA 2021 meeting, from Clinical Care Options (CCO)

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, FMedSci María-Victoria Mateos, MD, PhD Lydia Scarfò, MD Ali T. Taher, MD, PhD, FRCP Released: July 28, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue